Imagery as Biomarker of Gout
Launched by LILLE CATHOLIC UNIVERSITY · Jun 27, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Imagery as Biomarker of Gout," is investigating whether certain deposits of crystals in the body, which can be seen using ultrasound or a special type of imaging called DECT, are linked to the development of gout in people with high uric acid levels. Gout is a painful condition that can occur when too much uric acid builds up in the body. The study will follow participants for five years to see if those with these crystal deposits develop symptoms of gout.
To participate in this study, individuals must be between 18 and 80 years old and have a high level of uric acid in their blood but should not currently have any symptoms of gout. Participants will undergo imaging tests to check for crystal deposits. It's important to note that individuals with certain serious health conditions, those who have previously had gout symptoms, or those currently taking specific medications for gout will not be eligible. This trial aims to better understand how crystal deposits relate to the onset of gout, which could help improve future prevention and treatment strategies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Serum urate level ≥ 80 mg/L on inclusion,
- • No current or previous clinical symptoms of gout (including clinically apparent flares or tophus),
- • Between 18 and 80 years old,
- • Able to give informed consent.
- Exclusion Criteria:
- • GFR (glomerular filtration rate) \<30 ml / min / 1.73 m² or dialysis,
- • Serious illness with a poor prognosis of less than 5 years,
- • Autoimmune inflammatory arthritis,
- • Change of geographical area within 5 years,
- • Previous analysis of synovial fluid showing crystals of MSU,
- • Presence of subcutaneous tophi,
- • Taking a hypouricaemic treatment (allopurinol, probenecid, benzbromarone, febuxostat, lesinurad), canakinumab, anakinra or colchicine,
- • Uricemia observed only after an acute decompensation of comorbidity
- • Pregnant or breastfeeding women
About Lille Catholic University
Lille Catholic University, a prominent academic institution in France, is dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university integrates expertise from various fields to foster the development of cutting-edge medical solutions. Its commitment to ethical standards and patient-centered approaches ensures that clinical trials conducted under its auspices are rigorous, scientifically sound, and aligned with the highest standards of care. By leveraging its extensive network of researchers, healthcare professionals, and resources, Lille Catholic University plays a vital role in contributing to the enhancement of medical knowledge and the improvement of patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lille, Nord Pas De Calais, France
Patients applied
Trial Officials
Tristan Pascart, MD, PhD
Principal Investigator
Lille Catholic University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials